160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects completing the 48 week placebo-controlled period will receive…
- Investigator
- Ali Ataya
- Ages
- 18 Years - N/A
- Sexes
- All